CareDx (CDNA) Announces Closure of DOJ Investigation with No Finding of Wrongdoing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing
October 8, 2024 6:05 AM EDTDOJ Concludes Investigation and Declines to Prosecute
BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced that the Department of Justice (DOJ) has concluded its investigation into CareDx with no finding of wrongdoing and declined to take any further action.
In a Court document unsealed on October 7, 2024, the DOJ indicated that it is declining to intervene in a qui tam... More
